Shares of Biogen Inc. BIIB shed 2.06% to $160.85 Tuesday, on what proved to be an all-around mixed trading session for the ...

Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...

On Monday, Biogen Inc (BIIB) stock saw a modest uptick, ending the day at $164.23 which represents a slight increase of $3.60 or 2.24% from the prior close of $160.63. The stock opened at $160.16 and ...

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

On Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) presented detailed results from the Phase 3 PHOENYCS ...

The Manufacturers Life Insurance Company lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1.8% ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

Today, Benzinga 's options scanner spotted 9 uncommon options trades for Biogen. This isn't normal. The overall sentiment of ...

On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ.

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...